Benvenuti nel sito del Gruppo Oncologico del Nord Ovest

Chi Siamo Mission

Scopri i Centri Partecipanti

Guarda Contattaci

Pubblicazioni 2018

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO Annals of Oncology 0: 1–7, 2018 doi:10.1093/annonc/mdy004 Published online 8 January 2018 Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and…

Pubblicazioni 2017 – 2014

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017 TRIBE-2: a phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group BMC Cancer (2017) 17:408 DOI 10.1186/s12885-017-3360-z Serum LDH…

Pubblicazioni 2013 – 2004

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Outcome of second-line treatment after first-line chemotherapy with the GONO…